Frontlight ResearchEarly access
Crohn's disease trials in United Kingdom
30 of 39 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Where
- Bristol, Cambridge, Doncaster, Exeter, Huddersfield, London, Oxford, Southampton, West Midlands
- Age
- 16 years to 80 years
- People
- 1,200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00 - Phase 3Taking peopleA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Cambridge, Harrow, Liverpool, London, Newcastle upon Tyne, North Shields, Nottingham
- Age
- 16 years to 80 years
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00 - No phaseNot yet taking people in United KingdomHBOT for Perianal Crohn's Disease
- Where
- London
- Age
- 18 years and over
- People
- 10
- Run by
- Barts & The London NHS Trust
See details and how to joinNCT07934407 - Phase 3Taking peopleExtension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Where
- London, Prescot
- Age
- 18 years and over
- People
- 1,380 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06651281 · EU 2024-513533-20-00 - Phase 3Taking peopleA Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
- Where
- Birmingham, London, Sheffield
- Age
- 2 years to 17 years
- People
- 100 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07298421 · EU 2025-523318-96-00 - Phase 3Taking peopleA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Glasgow, London, Manchester, Oxford, Sheffield
- Age
- 2 years to 17 years
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00 - Phase 3Taking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Sheffield, Stoke-on-Trent
- Age
- 3 years to 64 years
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - Phase 2/3Taking peopleA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Birmingham, Cambridge, Glasgow, Greater Manchester, London, Rainhill, Stockport
- Age
- 18 years and over
- People
- 1,092 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00 - No phaseTaking peopleA Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease
- Where
- Bury, Cambridge, Cottingham, Dudley, Llandough, London, Oxford, Southampton, Winchester
- Age
- 18 years and over
- People
- 378 worldwide
- Run by
- Alimentiv Inc.
See details and how to joinNCT07363044 - Phase 3Taking peopleA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Greater London, Iselworth, London, Norwich, Wolverhampton
- Age
- 18 years and over
- People
- 530 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07499232 - Phase 3Taking peopleA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Birmingham, Bury, Cardiff, Dundee, Dundonald, Exeter, Glasgow, London, Newcastle upon Tyne, Oxford
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00 - Phase 2Taking peopleA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Where
- Belfast, Cambridge, London
- Age
- 18 years to 75 years
- People
- 268 worldwide
- Run by
- Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00 - Phase 2Taking peopleA Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
- Where
- Bury, Cambridge, Dagenham, London
- Age
- 18 years to 75 years
- People
- 99 worldwide
- Run by
- Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00 - Phase 2Taking peopleNOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease
- Where
- London
- Age
- 18 years and over
- People
- 320 worldwide
- Run by
- Agomab Spain S.L.U.
See details and how to joinNCT07683325 - Phase 3Taking peopleA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Bristol, Bury, Llanrhystud, London, Newcastle upon Tyne, Stockport
- Age
- 16 years to 80 years
- People
- 425 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00 - Phase 3Taking peopleAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Cambridge, Cottingham, London, Norwich, Rochdale
- Age
- 16 years to 80 years
- People
- 980 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184931 - Phase 3Taking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Birmingham, London, Sheffield
- Age
- 2 years to 17 years
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00 - Phase 3Taking peopleA Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Where
- London, Oxford, Sheffield
- Age
- 2 years to 19 years
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT04844606 - Phase 3Taking peopleA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Where
- Edinburgh, Headington, London, Manchester, Sheffield, Whitechapel
- Age
- 2 years to 17 years
- People
- 90 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00 - Phase 2Taking peopleStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Where
- Bristol, Cardiff, Coventry, Edinburgh, Glasgow, London, Newcastle upon Tyne, Oxford, Wolverhampton
- Age
- 18 years to 75 years
- People
- 590 worldwide
- Run by
- AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00 - Phase 2Taking peopleA Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease
- Where
- Oxford
- Age
- 18 years to 75 years
- People
- 20
- Run by
- Takeda
See details and how to joinNCT07403968 - Phase 4Taking peopleStopping PPI Therapy in Inactive IBD
- Where
- Nottingham
- Age
- 16 years and over
- People
- 80
- Run by
- University of Nottingham
See details and how to joinNCT07691138 - Phase 3Not yet taking people in United KingdomA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Where
- Edinburgh, Glasgow, London
- Age
- 18 years to 65 years
- People
- 396 worldwide
- Run by
- Takeda
See details and how to joinNCT06227910 · EU 2023-509391-42-00 - Phase 3Taking peopleA Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Where
- Birmingham, Cardiff, London, Manchester
- Age
- 2 years to 17 years
- People
- 240 worldwide
- Run by
- Takeda
See details and how to joinNCT05442567 · EU 2023-509046-36-00 - Phase 3Not yet taking people in United KingdomA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Where
- Birmingham, Cardiff, London, Manchester
- Age
- 2 years to 17 years
- People
- 120 worldwide
- Run by
- Takeda
See details and how to joinNCT04779320 · EU 2023-509045-13-00